Full Year 2023 Investor Presentation

78 Investor presentation Full year 2023 Novo NordiskⓇ The STEP HFPEF-DM trial was successfully completed in Q4 2023 and is to be included in the regulatory submission STEP HFPEF-DM trial with 610 people with obesity, HFPEF and T2D Trial design and next steps Dual primary endpoints: • Change in KCCQ from baseline to week 52 Semaglutide 2.4 mg + SoC R 1:1 Placebo + SoC • Change in body weight from baseline to week 52 Inclusion criteria: • BMI ≥30 kg/m2 • NYHA II-IV Ejection fraction ≥45% Dose escalation Treatment maintenance Follow up 16 weeks . HbA1c ≤10.0% 36 weeks 5 weeks Status: • Completion of STEP HFPEF-DM trial in November 2023 • Combined (including STEP HFpEF trial) regulatory submission of both trials in H1 2024 R: Randomisation; HF: Heart Failure; HFPEF: Heart Failure with preserved ejection fraction; SoC: Standard of care; KCCQ: Kansas City Cardiomyopathy Questionnaire; 6MWD: 6-min walking distance; NYHA: New York Heart Association classification

View entire presentation